Business Wire

VA-SES

3.6.2021 08:52:10 CEST | Business Wire | Press release

Share
Isotropic Systems and SES GS Complete Milestone Trials to Unlock Next-Gen Connectivity for U.S. Military

SES Government Solutions (SES GS), a wholly-owned subsidiary of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, announce the successful completion of the first of two milestone next-generation antenna trials with the U.S. Military aimed at unleashing unprecedented information distribution to warfighters across the battlefield.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602006167/en/

The U.S. Air Force and U.S. Army, through the innovative Defense Experimentation Using Commercial Space Internet (DEUCSI) program, are evaluating the ability of Isotropic Systems’ optical beamforming antenna to enable frontline armed forces to access high-speed, real-time data simultaneously over multiple commercial and military satellites.

First phase dual-beam tests conducted at the Harwell Science, Technology and Innovation Campus near Oxford, UK, have successfully demonstrated transformational optics at the core of Isotropic Systems’ multi-beam terminal that are fully capable of linking with multiple satellites at the same time.

Over-the-air (OTA) trials conducted at an SES teleport in Port St. Lucie, Florida, also part of phase one, have verified the Isotropic Systems’ high-performance multi-beam platform meets military requirements to acquire and track SES’ O3b MEO satellites.

Phase two trials will test Isotropic Systems’ latest antenna prototype over links with SES satellites in geostationary orbit (GEO) and medium earth orbit (MEO), demonstrating seamless satellite-to-satellite transitions and a redundant, resilient leap in wartime communications.

The DEUCSI trials will wrap up in 2021, ahead of the commercial launch of Isotropic Systems’ optical multi-beam antenna production scheduled for 2022, and in time to support SES’ new high-throughput MEO constellation satellites coming online, the groundbreaking O3b mPOWER system.

“The armed forces and defense agencies are incredibly good at acquiring actionable information, but they run into bottlenecks when they try to distribute that mission-critical data over single beam parabolic antennas and other outdated infrastructure,” said Scott Sprague, Isotropic Systems CCO. “These milestone trials with the U.S. Army and Air Force are successfully demonstrating the multi-beam, multi-orbit connectivity and capabilities our high-performance terminals will put in the hands of frontline warfighters and decision makers across the government sector and battlespace.”

“Next-gen satellites and constellations need equally robust and resilient terminals and ground infrastructure to meet the government’s ’Fighting SATCOM’ vision,” said Pete Hoene, President and CEO of SES Government Solutions, Brigadier General, USAF (Ret.). “Interoperability and multi-orbit capabilities are essential to achieving this vision, and these collaborative trials with the armed forces demonstrate how Isotropic Systems’ multi-beam antenna can successfully deliver robust connectivity across our vast MEO and GEO fleet. Each successful phase is a prime example of how the government and commercial partners can develop capabilities in parallel, which is especially important to us as we ready to launch our O3b mPOWER constellation and SES-17 satellite this year.

“Without affecting the main communications link, the Isotropic Systems multi-beam terminal can use a second or third link to evaluate the environment to preemptively decide the best routing option at any given time to maximize performance,” explained Brian Billman, Vice President of Product Management for Isotropic Systems. “That’s the level of differentiating capabilities our terminal roadmap leads to as a result of these important trials with the U.S. military.”

For further information please contact:

About SES Government Solutions

SES Government Solutions (SES GS) is a wholly-owned subsidiary of SES, the leader in global content connectivity solutions. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES GS offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com .

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

About Isotropic Systems

Isotropic Systems is developing the world’s first multi-service, high-bandwidth, low power, fully integrated high throughput terminals designed to support the satellite industry to 'reach beyond' traditional markets and acquire new customers with a full suite of high throughput services. The company’s team of industry experts and scientists has pioneered several firsts in satellite terminal design resulting in a line of terminals that are customizable to meet the performance, cost and power requirements of countless applications – from the most complex government defense systems and mobile backhaul solutions capable of extending 5G, to next-gen connected experiences aboard commercial airliners, cruise ships, offshore rigs, and even small fishing boats at sea. Isotropic Systems’ Series A funding was led by Boeing to advance space-based connectivity. Further information is available at www.isotropicsystems.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye